Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Issue 7 (30th July 2020)

• Record Type: Journal Article
• Authors: Du, Jiali; Gu, Jichun; Li, Ji
• Is Part Of: Bioscience reports. Volume 40:Issue 7(2020)
• Publication Date: 2020-07-30
• Subjects: Cellular immunotherapies -- Drug resistance -- Gemcitabine -- Molecular targeted therapy -- Pancreatic ductal adenocarcinoma (PDAC); Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20200401
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwide, and the mortality of patients with PDAC has not significantly decreased over the last few decades. Novel strategies exhibiting promising effects in preclinical or phase I/II clinical trials are often situated in an embarrassing condition owing to the disappointing results in phase III trials. The efficacy of the current therapeutic regimens is consistently compromised by the mechanisms of drug resistance at different levels, distinctly more intractable than several other solid tumours. In this review, the main mechanisms of drug resistance clinicians and investigators are dealing with during the exploitation and exploration of the anti-tumour effects of drugs in PDAC treatment are summarized. Corresponding measures to overcome these limitations are also discussed.